-+ 0.00%
-+ 0.00%
-+ 0.00%

Chugai Pharma FY26 Q2 net income climbs 19.2% to ¥231.7 billion; revenue rises 14.7% to ¥663.3 billion

PUBT·07/24/2026 07:06:22
Listen to the news
Chugai Pharma FY26 Q2 net income climbs 19.2% to ¥231.7 billion; revenue rises 14.7% to ¥663.3 billion
  • Chugai Pharmaceutical posted IFRS revenue of ¥663.33 billion for the six months ended June 30, up 14.7% year on year; operating profit rose 16.9% to ¥319.62 billion.
  • IFRS net income attributable to shareholders climbed 19.2% to ¥231.75 billion; basic EPS increased to ¥140.82, up from the prior year period.
  • Core operating profit rose 21% to ¥329.14 billion, while core net income increased 23.2% to ¥238.37 billion.
  • Core revenue growth reflected higher sales and other revenue, with domestic sales lifted by Vabysmo and Polivy; overseas sales rose on higher Hemlibra and NEMLUVIO exports.
  • Chugai maintained its full-year forecast for revenue of ¥1,345 billion, core operating profit of ¥670 billion, and core net income of ¥485 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein.